Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 4, 2008

View Archived Issues

Proof-of-concept study supports development of NBI-34041 for anxiety

Postmarketing study finds no increase in nonsuicide death with ziprasidone compared to olanzapine

ASF-1096 investigated in discoid and subacute lupus erythematosus

Aripiprazole data in Asperger's disorder and major depressive disorder reported

Takeda patents use of resatorvid for coronary surgical procedure complications

Pfizer initiates Japanese phase II clinical study of PF-03187207 for glaucoma

NCI files protocol for phase I/II clinical trial of Oncolytics' cancer drug Reolysin

Lundbeck begins phase I clinical studies of Lu-AA-37096 and stops development of Lu-AA-44608

GenVec makes protocol changes to phase II/III PACT trial of TNFerade for pancreatic cancer

ImmunoGen licenses exclusive right to develop IMGN-388 using Centocor antibody

Addex and Merck & Co. to codevelop drug candidate for schizophrenia

FDA approves Shire's new dosages for ADHD treatment Vyvanse

Xanthus' oral fludarabine therapy for CLL receives orphan drug designation

Recent Thallion patent discloses novel antiinfective agents

Recent Bayer patents report novel antithrombotic agents

New phase I/II trial for ispinesib monotherapy in metastatic breast cancer begins

XenoPort begins several clinical trials, gives update on other pipeline products

Amic enters license agreement with Roche Diagnostics for test for cardiac marker NT-proBNP

Takeda submits NDA for alogliptin in the U.S.

Addex announces ADX-10059 phase IIa acute anxiety data

Anti-HIV drug apricitabine enters phase III

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 8, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...